Want to see NBIX full AI Analyst Report?
NBIX Stock Chart & Stats
$133.25
$0.29(0.21%)
At close: 4:00 PM EST
$133.25
$0.29(0.21%)
Day’s Range― - ―
52-Week Range$122.14 - $181.18
Previous CloseN/A
Volume209.65K
Average Volume (3M)1.11M
Market Cap
$17.40B
Enterprise Value$12.71K
Total Cash (Recent Filing)$1.32B
Total Debt (Recent Filing)$406.20M
Price to Earnings (P/E)25.8
Beta0.63
Next Earnings
Jul 30, 2026EPS Estimate
1.62Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)6.71
Shares Outstanding100,549,980
10 Day Avg. Volume1,067,478
30 Day Avg. Volume1,108,943
Financial Highlights & Ratios
PEG Ratio0.71
Price to Book (P/B)4.34
Price to Sales (P/S)4.93
P/FCF Ratio18.85
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price Target
$199.70Price Target Upside49.87% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering24
EPS Forecast (FY)7.67
Revenue Forecast (FY)$3.76B
Bulls Say, Bears Say
Bulls Say
Very High Gross Margins And Improving ProfitabilitySustained ~98% gross margins and expanding operating/net margins reflect a high‑value, product‑led business model with strong pricing and low cost of goods. Durable margin structure supports reinvestment in R&D and commercialization, providing a long‑term cushion for profit expansion despite cyclical sales swings.
Strong Free Cash Flow ConversionVery high FCF conversion (FCF ≈96% of net income) signals high earnings quality and reliable cash generation from operations. This durable cash flow funds R&D, acquisitions, and commercialization without heavy reliance on external funding, increasing financial flexibility over a multi‑year horizon.
Acquisition Expands Rare Disease Portfolio (VYKAT XR)Closing Soleno brings VYKAT XR, the first approved hyperphagia therapy, expanding Neurocrine into rare disease/endocrinology. This diversifies revenue away from core neurology products, creates cross‑selling and commercial scale benefits, and lengthens the company’s structural growth runway over coming years.
Bears Say
Product Concentration & Early Adoption RiskDespite strong INGREZZA sales, material revenue concentration remains while Cranesity/VYKAT XR are early commercial launches. Low penetration and limited prescriber experience mean realized growth depends on converting broader prescriber bases and sustained payer support, making near‑term revenue cadence uneven.
Pipeline Timing And Execution RiskR&D momentum is real but clustered: key readouts (e.g., obesity, MDD, schizophrenia programs) are multi‑year away and hinge on successful trials and regulatory progress. The long timelines and binary outcomes mean significant uncertainty in converting pipeline investment into commercial revenue over the 2–6 month horizon and beyond.
Acquisition Financing Increases Covenant And Liquidity RiskTo fund Soleno integration Neurocrine drew $600M on a secured $1B revolver, introducing leverage and coverage covenants. While the balance sheet was previously conservative, added secured borrowing tightens financial flexibility and could constrain capital allocation or require deleveraging if cash flow or interest rates deteriorate.
Neurocrine News
NBIX FAQ
What was Neurocrine Biosciences’s price range in the past 12 months?
Neurocrine Biosciences lowest stock price was $122.14 and its highest was $181.18 in the past 12 months.
What is Neurocrine Biosciences’s market cap?
Neurocrine Biosciences’s market cap is $17.40B.
When is Neurocrine Biosciences’s upcoming earnings report date?
Neurocrine Biosciences’s upcoming earnings report date is Jul 30, 2026 which is in 8 days.
How were Neurocrine Biosciences’s earnings last quarter?
Neurocrine Biosciences released its earnings results on May 05, 2026. The company reported $1.91 earnings per share for the quarter, beating the consensus estimate of $1.216 by $0.694.
Is Neurocrine Biosciences overvalued?
According to Wall Street analysts Neurocrine Biosciences’s price is currently Undervalued.
Does Neurocrine Biosciences pay dividends?
Neurocrine Biosciences does not currently pay dividends.
What is Neurocrine Biosciences’s EPS estimate?
Neurocrine Biosciences’s EPS estimate is 1.62.
How many shares outstanding does Neurocrine Biosciences have?
Neurocrine Biosciences has 100,549,980 shares outstanding.
What happened to Neurocrine Biosciences’s price movement after its last earnings report?
Neurocrine Biosciences reported an EPS of $1.91 in its last earnings report, beating expectations of $1.216. Following the earnings report the stock price went up 8.855%.
Which hedge fund is a major shareholder of Neurocrine Biosciences?
Currently, no hedge funds are holding shares in NBIX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Neurocrine Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$199.70 (49.87% Upside)
$199.70 (49.87% Upside)
Blogger Sentiment
Bullish
NBIX Sentiment 70%
Sector Average 66%
Sector Average 66%
Hedge Fund Trend
Decreased
By 1.1M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 0.5%
Last 30 Days ▲ 28.7%
Last 30 Days ▲ 28.7%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
31.04%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
33.04%
Trailing 12-Months
Company Description
Neurocrine Biosciences
Neurocrine Biosciences, Inc. is a pharmaceutical firm dedicated to the creation, advancement, and commercialization of medicines addressing a spectrum of neurological, endocrine, and psychiatric conditions. Its current therapeutic pipeline and marketed products target disorders such as tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, alongside numerous experimental compounds in various clinical stages. The company's primary commercial asset is INGREZZA, a VMAT2 inhibitor indicated for the management of tardive dyskinesia. Other available treatments include ONGENTYS, which serves as an auxiliary therapy for individuals with Parkinson's disease who are also receiving levodopa/DOPA decarboxylase inhibitors; ORILISSA, prescribed for the alleviation of moderate to severe pain linked with endometriosis in women; and ORIAHNN, an oral, non-surgical option for pre-menopausal women experiencing significant menstrual bleeding associated with uterine fibroids. Furthermore, Neurocrine is actively progressing a number of drug candidates through clinical development. These include NBI-921352 for treating pediatric patients and adult focal epilepsy; NBI-827104, designed to address rare pediatric epilepsy and essential tremor; NBI-1065845 for major depressive disorder; NBI-1065846 specifically for anhedonia within major depressive disorder; and NBI-118568 for the treatment of schizophrenia. The company also maintains strategic licensing and collaborative ventures with partners such as Heptares Therapeutics Limited, Takeda Pharmaceutical Company Limited, Idorsia Pharmaceuticals Ltd, Xenon Pharmaceuticals Inc., Voyager Therapeutics, Inc., BIAL Portela & Ca, S.A., Mitsubishi Tanabe Pharma Corporation, and AbbVie Inc. Neurocrine Biosciences, Inc. was founded in 1992 and operates from its headquarters in San Diego, California.
NBIX Stock 12 Month Forecast
Average Price Target
$199.70
▲(49.87% Upside)
Technical Analysis
Dr Reddy's Laboratories
―
Viatris
―
Pacira Pharmaceuticals
―
Teva Pharmaceutical
―
Amphastar Pharmaceuticals
―
Ownership Overview
1.14% Insiders
25.39% Mutual Funds
1.03% Other Institutional Investors
41.25% Public Companies and
Individual Investors